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CARDIOVASCULAR MEDICINE
Hypercholesterolaemia and lipid lowering treatment do
not affect the acute endogenous fibrinolytic capacity in
vivo
D E Newby, F N Witherow, R A Wright, P Bloomfield, C A Ludlam, N A Boon,
K A A Fox, D J Webb
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Objective: To assess acute tissue plasminogen activator (t-PA) release in vivo in patients with hyper-
cholesterolaemia in the presence and absence of lipid lowering treatment and in matched normocho-
lesterolaemic controls.
Design: Parallel group comparison and double blind randomised crossover.
Setting: University hospital.
Patients: Eight patients with hypercholesterolaemia (> 7.8 mmol/l) and eight matched normocholes-
terolaemic controls (< 5.5 mmol/l).
Methods: Blood flow and plasma fibrinolytic factors were measured in both forearms during unilateral
brachial artery infusions of the endothelium dependent vasodilator substance P (2–8 pmol/min) and the
endothelium independent vasodilator sodium nitroprusside (1–4 µg/min).
Interventions: In patients, measurements were made on three occasions: at baseline and after six
weeks of placebo or pravastatin 40 mg daily administered in a double blind randomised crossover
design.
Main outcome measures: Acute release of t-PA.
Results: Compared with patients, in normocholesterolaemic control subjects substance P caused
greater dose dependent increases in forearm blood flow (p < 0.05) but similar increases in plasma t-PA
antigen and activity concentrations. During pravastatin treatment in patients, total serum cholesterol fell
by 22% from a mean (SEM) of 8.1 (0.3) to 6.4 (0.4) mmol/l (p = 0.002) and substance P induced
vasodilatation was no longer significantly impaired in comparison with controls. However, despite
reproducible responses, pravastatin treatment was not associated with significant changes in basal or
substance P induced t-PA release.
Conclusions: Hypercholesterolaemia and lipid lowering treatment cause no demonstrable effects on
acute substance P induced t-PA release in vivo. This suggests that the preventative benefits of lipid low-
ering treatment are unlikely to be mediated by improvements in endogenous fibrinolysis.
Hypercholesterolaemia impairs endothelial cellfunction,1–3 predisposes vessels to damage, and contrib-utes to vascular occlusion.4 Previous studies have shown
that endothelium dependent nitric oxide mediated vasodilata-
tion is impaired in patients with hypercholesterolaemia,1–3 an
effect that is reversed by lipid lowering treatment.5–7 Although
other endothelial cell markers have been described,8 9 the
fibrinolytic factor tissue plasminogen activator (t-PA) and its
inhibitor, plasminogen activator inhibitor type 1 (PAI-1), are
potentially important markers that are intimately linked to
the risk of atherothrombosis.10 11
Endothelial cells in the precapillary arterioles and postcap-
illary venules12 synthesise and release t-PA and PAI-1 both
basally and in response to various coagulation factors and
stimulants. The rapid mobilisation of t-PA from the endothe-
lium is crucial if endogenous fibrinolysis within the arterial
circulation is to be effective, with thrombus dissolution being
much more effective if t-PA is incorporated during, rather than
after, thrombus formation.13 14 The importance of endogenous
t-PA release is exemplified by the high rate of spontaneous
reperfusion in the infarct related artery after acute myocardial
infarction, which occurs in around 30% of patients within the
first 12 hours.15
Epidemiological studies examining total plasma t-PA and
PAI-1 concentrations in patients with ischaemic heart disease
have observed a positive correlation with coronary events.10 11
It would be anticipated, however, that high t-PA concentra-
tions would protect against subsequent coronary events rather
than the reverse. This paradoxical association is, in part,
explained by the concomitant increase of PAI-1, which
complexes with t-PA and therefore causes an overall reduction
in free t-PA “activity”.16 17 It is this free and unbound t-PA that
is physiologically active and central to endogenous fibrinoly-
sis. However, the capacity of endothelial cells to release t-PA
from intracellular storage pools and the rapidity with which
this can be mobilised may not necessarily be reflected in the
basal circulating plasma concentrations of t-PA antigen or its
activity.18 19 We have recently described an in vivo model to
assess the acute release of t-PA in the forearm of humans.20
Using intrabrachial infusions of substance P, we have shown a
dose dependent release of t-PA without causing a significant
release in PAI-1. Moreover, we have also reported21 that t-PA
release is inhibited by nitric oxide synthase inhibition with
L-NG-monomethylarginine, suggesting that endothelial dys-
function may impair the release of t-PA.
Given that substance P induced vasodilatation has
been reported to be impaired in patients with
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hypercholesterolaemia,3 the aims of the present study were to
determine whether there is also an impairment of t-PA release
in patients with hypercholesterolaemia and whether treat-
ment with pravastatin5 could enhance t-PA release in these
patients.
METHODS
Patients and control subjects
Eight patients with primary hypercholesterolaemia were
recruited from the clinic if their serum cholesterol concentra-
tions exceeded 7.8 mmol/l (> 296 mg/dl). Following screening
with clinical examination, repeated questioning for symp-
toms, clinical chemistry screen (liver enzymes, electrolytes,
urea, and creatine), haematology screen (full blood and
differential counts), urinalysis, and 12 lead ECG, patients were
excluded if they had diabetes mellitus, hypertension, ischae-
mic heart disease, peripheral vascular disease, an abnormal
resting ECG, or other clinically significant disease. Patients
were matched with normocholesterolaemic (< 5.5 mmol/l;
< 209 mg/dl) healthy control subjects for age, sex, and smok-
ing habit. All studies were undertaken with the approval of
the local research ethics committee and in accordance with
the Declaration of Helsinki. The written informed consent of
each subject was obtained before entry into the study. None of
the subjects was receiving vasoactive or non-steroidal anti-
inflammatory drugs in the week before each phase of the
study, and all abstained from alcohol for 24 hours and from
food, tobacco, and drinks containing caffeine for at least nine
hours before each study. All studies were performed in a quiet
temperature controlled room maintained at 23.5–24.5°C.
Intra-arterial administration and drugs
The brachial artery of the non-dominant arm was cannulated
with a 27 standard wire gauge steel needle (Cooper’s Needle
Works Ltd, Birmingham, UK) under 1% lignocaine (Xylocaine;
Astra Pharmaceuticals Ltd, Kings Langley, UK) local anaesthe-
sia. The cannula was attached to a 16 gauge epidural catheter
(Portex Ltd, Hythe, UK) and patency was maintained by infu-
sion of saline (0.9%; Baxter Healthcare Ltd, Thetford, UK)
through an IVAC P1000 syringe pump (IVAC Ltd, Basingstoke,
UK). The total rate of intra-arterial infusions was maintained
constant throughout all studies at 1 ml/min. Pharmaceutical
grade substance P (Clinalfa AG, Läufelfingen, Switzerland)
and sodium nitroprusside (David Bull Laboratories, Warwick,
UK) were administered following dissolution in saline.
Forearm blood flow and blood pressure
Blood flow was measured in both forearms by venous
occlusion plethysmography using mercury in silastic strain
gauges applied to the widest part of the forearm.22 During
measurement periods the hands were excluded from the
circulation by rapid inflation of the wrist cuffs to a pressure of
220 mm Hg using E20 rapid cuff inflators (DE Hokanson Inc,
Bellevue, Washington, USA). Upper arm cuffs were inflated
intermittently to 40 mm Hg for 10 s in every 15 s to achieve
venous occlusion and obtain plethysmographic recordings.
Analogue voltage output from an EC-4 strain gauge plethys-
mograph (DE Hokanson) was processed by a MacLab
analogue to digital converter and Chart version 3.3.8 software
(AD Instruments Ltd, Castle Hill, Australia) and recorded on
to a MacIntosh Classic II computer (Apple Computers Inc,
Cupertino, California USA). Calibration was achieved using
the internal standard of the plethysmograph.
Blood pressure was monitored in the non-infused arm at
intervals throughout each study using a semiautomated non-
invasive oscillometric sphygmomanometer (Takeda UA 751,
Takeda Medical Inc, Tokyo, Japan).23
Venous sampling and assays
Venous cannulae (17 gauge) were inserted into large
subcutaneous veins of the antecubital fossa in both arms. Ten
millilitres of blood was withdrawn simultaneously from each
arm and collected into acidified buffered citrate (Biopool Sta-
bilyte, Umeå, Sweden, for t-PA assays) and citrate (Monovette,
Sarstedt, Nümbrecht, Germany, for PAI-1 assays) tubes, and
kept on ice before being centrifuged at 2000 g for 30 minutes
at 4°C. Platelet free plasma was decanted and stored at −80°C
before assay.24
Plasma t-PA and PAI-1 antigen concentrations were
determined using an enzyme linked immunosorbent assay
(ELISA): Coaliza t-PA25 and Coaliza PAI-126 (Chromogenix AB,
Mölndal, Sweden), respectively. Plasma t-PA and PAI-1 activi-
ties were determined by a photometric method: Coaset t-PA
and Coatest PAI-1 (Chromogenix AB), respectively.27 Plasma
PAI-1 activity is determined by a back titration method and
represents the total t-PA inhibitory activity of the plasma.27 All
fibrinolytic assays were performed in duplicate and the mean
value was taken. Intra-assay coefficients of variation were
7.0% and 5.5% for t-PA and PAI-1 antigen and 4.0% and 2.4%
for activity, respectively. Interassay coefficients of variability
were 4.0%, 7.3%, 4.0% and 7.6%, respectively. The limits of
sensitivity of the assays were 0.5 ng/ml, 2.5 ng/ml, 0.10 IU/ml,
and 5 AU/ml, respectively. Haematocrit (Hct) was determined
by capillary tube centrifugation of blood anticoagulated by
ethylene diamine tetra-acetic acid and was obtained from the
infused forearm at baseline and at 8 pmol/min of substance P.
Serum cholesterol and triglyceride concentrations were deter-
mined by an enzymatic colorimetric method (Boehringer
Mannheim GmbH Diagnostica, Mannheim, Germany). Low
density lipoprotein (LDL) cholesterol was determined by the
method of Friedewald and colleagues.28
Study design
All patients attended on each of the three study days: baseline
and following six weeks’ treatment with placebo and six
weeks’ treatment with pravastatin 40 mg daily. Placebo and
pravastatin treatments were given in a randomised double
blind crossover design. Control subjects attended on one occa-
sion only.
On each study day, subjects attended fasted at 0900 and
rested recumbent throughout. Strain gauges and cuffs were
applied and the brachial artery of the non-dominant arm was
cannulated. Throughout all protocols, forearm blood flow
(FBF) was measured every 10 minutes. Before administration
of substance P and sodium nitroprusside, saline was infused
for 30 minutes to allow time for equilibration and the final
blood flow measurement during saline infusion was taken as
the basal FBF. Substance P was infused at 2, 4, and 8 pmol/min
for 10 minutes at each dose19–21 and sodium nitroprusside was
infused at 1, 2, and 4 µg/min for 10 minutes at each dose.20 The
order of administration of substance P and sodium nitroprus-
side was randomised.
Data analysis and statistics
Plethysmographic data were extracted from the Chart data
files and FBFs were calculated for individual venous occlusion
cuff inflations by use of a template spreadsheet (Excel version
5.0; Microsoft Corporation, Redmond, Washington, USA).
Recordings from the first 60 seconds after wrist cuff inflation
were not used because of the variability in blood flow that this
causes.22 Usually the last five flow recordings in each three
minute measurement period were calculated and averaged for
each arm. To reduce the variability of blood flow data, the ratio
of flows in the two arms was calculated for each time point, in
effect using the non-infused arm as a contemporaneous con-
trol for the infused arm.22 Percentage changes in the infused
FBF were calculated22 as follows:
% change in blood flow = 100 × (It/NIt − Ib/NIb) / Ib/NIb
where Ib and NIb are the infused and non-infused FBFs at
baseline (time 0), respectively, and It and NIt are the infused
and non-infused FBFs at a given time point, respectively.
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Estimated net release of t-PA activity and antigen was
defined previously19–21 as the product of the infused forearm
plasma flow (based on the mean Hct and the infused FBF) and
the concentration difference between the infused ([t-PA]Inf)
and non-infused arms ([t-PA]Non-inf):
estimated net t-PA release = FBF × (1 − Hct) × ([t-PA]Inf −
[t-PA]Non-inf)
Data were examined, where appropriate, by two way analysis
of variance with repeated measures and two tailed paired Stu-
dent’s t test using Excel version 5.0. Reproducibility of the
responses to substance P infusion was assessed by comparing
the baseline data with placebo treatment study days using the
method of Bland and Altman.29 Coefficients of reproducibility
were determined for 95% confidence intervals using the Stu-
dent’s t distribution. All results are expressed as mean (SEM).
Significance was taken at the 5% level. On the basis of previ-
ous data20 the study had 90% power to detect a 20% change in
plasma t-PA concentrations between treatment periods at the
5% level.
RESULTS
Table 1 shows patient and control subject characteristics. The
groups were well matched for age, sex, body mass index,
smoking habit, blood pressure, heart rate, Hct, and FBF. Total
cholesterol and LDL cholesterol concentrations were signifi-
cantly higher in the patient group and fell during pravastatin
but not placebo treatment (table 1). On each of the study days
in the patient and control groups, blood pressure, heart rate,
Hct, blood flow, and t-PA concentrations of the non-infused
forearm did not change.
Blood flow responses
Substance P caused dose dependent increases in blood flow of
the infused forearm in both patients and controls (p < 0.001
for both, analysis of variance; fig 1). In comparison to the con-
trol group, the substance P induced increases in blood flow
were significantly less in the patient group (p < 0.05, two way
analysis of variance; fig 1). During pravastatin treatment, sub-
stance P appeared to cause a slightly greater increase in blood
flow but this was not significantly different from baseline
responses (p = 0.30, two way analysis of variance, baseline
versus pravastatin) although it was no longer significantly
different from control group responses (p = 0.24, two way
analysis of variance).
Sodium nitroprusside also caused dose dependent increases
in blood flow of the infused forearm (p < 0.001, analysis of
Table 1 Lipid profile, haemodynamics, absolute forearm blood flow, and
haematocrit at baseline and during placebo and pravastatin treatment
Controls
Patients
Baseline Placebo Pravastatin
Age (years) 43 (3) 46 (3) – –
Sex (male:female) 5:3 5:3 – –
Body mass index (kg/m2) 24 (1) 25 (1) – –
Smokers 3 3 – –
Total cholesterol (mmol/l) 5.0 (0.2)*** 8.1 (0.3) 8.2 (0.3) 6.4 (0.4)**
LDL cholesterol (mmol/l) 3.2 (0.2)*** 5.8 (0.5) 6.1 (0.5) 4.3 (0.4)*
HDL cholesterol (mmol/l) 1.1 (0.1) 1.1 (0.1) 1.1 (0.2) 1.2 (0.2)
Triglycerides (mmol/l) 1.5 (0.4) 2.7 (0.4) 2.3 (0.4) 1.9 (0.3)
Mean arterial pressure (mm Hg) 88 (5) 87 (2) 87 (4) 87 (2)
Heart rate (beats/min) 64 (2) 62 (3) 63 (5) 62 (4)
Basal blood flow (mlL/100 ml/min)
Non-infused arm 3.0 (0.5) 2.4 (0.3) 2.9 (0.3) 2.4 (0.3)
Infused arm 3.7 (0.7) 3.6 (0.3) 3.2 (0.3) 2.5 (0.3)
Haematocrit 0.39 (0.01) 0.43 (0.01) 0.42 (0.01) 0.41 (0.01)
Data are mean (SEM). Unpaired t test ***p<0.001 (controls versus patients at baseline); *p=0.04,
**p=0.003 (patients: pravastatin versus controls); Paired t test *p=0.02, **p<0.003 (patients: placebo
versus pravastatin); Analysis of variance *p=0.04, **p<0.002 (three way analysis of variance for patient
groups).
HDL, high density lipoprotein; LDL, low density lipoprotein.
Figure 1 Forearm blood flow responses to substance P and sodium
nitroprusside administration in control subjects (open circles, upper
panels) and patients at baseline (closed circles, upper panels), and
in patients during placebo (open squares, lower panels) and during
pravastatin treatment (closed squares, lower panels). p < 0.001 for
each forearm blood flow response (one way analysis of variance).
*p < 0.05 (two way analysis of variance, controls versus patients).
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variance; fig 1), which were similar in patient and control
groups. Neither pravastatin nor placebo treatment influenced
the response to sodium nitroprusside infusion.
Fibrinolytic factor responses
Substance P caused dose dependent increases in plasma t-PA
antigen and activity concentrations in the infused forearm of
both patients and controls (p < 0.001 for both, analysis of
variance; table 2). Substance P induced increases in plasma
t-PA concentrations were similar in both groups and, in the
patient group, were unaffected by pravastatin or placebo
treatment. The concentration differences between the fore-
arms and the estimated net release of t-PA antigen and activ-
ity also increased dose dependently (p < 0.001, analysis of
variance; fig 2), which did not differ between the patient and
control groups or during pravastatin and placebo treatment.
There were no significant differences in plasma PAI-1 antigen
and activity concentrations at baseline, although there
appeared to be a trend for plasma PAI-1 antigen concentra-
tions to be lower in the control group (p > 0.12, unpaired
t test; table 3). Plasma PAI-1 concentrations were unaffected
by substance P infusion or pravastatin treatment (table 3).
Reproducibility of substance P responses
Comparison of responses at baseline and during placebo
treatment shows good reproducibility for substance P induced
increases in plasma t-PA concentrations and FBF (table 4).
DISCUSSION
Despite impaired endothelium dependent forearm vasodilata-
tion, we have shown that in patients with hypercholesterol-
aemia intrabrachial substance P infusions are associated with
a normal capacity to release t-PA acutely. Moreover, pravasta-
tin treatment, sufficient to reduce cholesterol concentrations
by 22%, had no significant effects on acute t-PA release. This
suggests that, despite the presence of endothelial dysfunction,
hypercholesterolaemia does not influence the acute fibrino-
lytic capacity of the endothelium and that the preventative
benefits of lipid lowering treatment are unlikely to be
mediated by improvements in endogenous fibrinolysis.
Consistent with previous findings,3 we have shown that in
patients with hypercholesterolaemia, endothelium dependent
vasodilatation in response to substance P infusion is impaired.
However, in contrast to the pronounced impairment of t-PA
release that we have recently described in cigarette smokers,19
hypercholesterolaemia and lipid lowering treatment do not
appear to influence substance P induced t-PA release. These
findings suggest that although smoking is associated with
impaired endogenous fibrinolysis, hypercholesterolaemia is
not. This is consistent with the observations that the patency
rate of the infarct related artery following thrombolytic treat-
ment during myocardial infarction is enhanced in cigarette
Table 2 Plasma tissue plasminogen activator (t-PA) antigen and activity in patients
at baseline and during placebo and pravastatin treatment and in a matched control
group
Substance P dose
(pmol/min) Controls
Patients
Baseline Placebo Pravastatin
t-PA antigen (ng/ml)
Infused forearm* 0 5.0 (0.5) 4.6 (0.8) 4.7 (0.6) 4.5 (0.6)
2 5.6 (0.7) 5.4 (0.8) 5.4 (0.6) 5.0 (0.4)
4 7.4 (0.8) 5.7 (0.9) 6.0 (0.9) 5.8 (0.6)
8 8.0 (1.3) 7.4 (1.1) 7.5 (1.3) 7.6 (1.1)
Non-infused forearm 0 4.7 (0.5) 4.8 (0.7) 4.5 (0.6) 4.6 (0.6)
2 4.6 (0.4) 4.8 (0.7) 4.5 (0.5) 4.5 (0.6)
4 5.8 (0.6) 5.1 (0.8) 4.5 (0.8) 4.6 (0.6)
8 5.7 (0.6) 5.0 (0.8) 5.1 (0.6) 4.8 (0.6)
t-PA activity (IU/ml)
Infused forearm* 0 0.6 (0.1) 0.5 (0.1) 0.6 (0.1) 0.5 (0.1)
2 1.7 (0.5) 1.3 (0.5) 1.1 (0.4) 1.6 (0.8)
4 2.7 (1.0) 2.0 (0.6) 1.7 (0.9) 2.2 (1.1)
8 4.5 (1.5) 3.4 (1.1) 3.9 (1.4) 3.1 (1.2)
Non-infused forearm 0 0.7 (0.1) 0.4 (0.1) 0.5 (0.1) 0.4 (0.1)
2 0.8 (0.1) 0.5 (0.1) 0.6 (0.2) 0.5 (0.1)
4 1.1 (0.2) 0.6 (0.1) 0.7 (0.2) 0.6 (0.1)
8 1.7 (0.5) 0.7 (0.2) 0.8 (0.2) 0.7 (0.2)
Data are mean (SEM). *p<0.001, one way analysis of variance in the infused forearm for each group.
Figure 2 Concentration difference between infused and
non-infused forearms (upper panels) and estimated net release (lower
panels) of plasma tissue plasminogen activator antigen (solid lines,
left panels) and activity (dashed lines, right panels) during substance
P administration in controls (open circles) and patients at baseline
(closed circles), and during placebo (open squares) and pravastatin
(closed squares) treatment. p < 0.001 for each response (one way
analysis of variance).
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smokers,30–32 but not in patients with hypercholesterolaemia,33
and that cigarette smoking is associated with thrombotic
occlusion whereas hypercholesterolaemia is linked to athero-
genesis and plaque rupture.4 This would also indicate that
endothelial dysfunction can be manifest in separate distinct
pathways depending on the nature of the insult.
The WOSCOPS (west of Scotland coronary prevention
study)34 was the first major randomised controlled trial to
show the primary preventative benefits of lipid lowering
therapy. We therefore chose to examine the effects of pravas-
tatin 40 mg daily on endothelial and fibrinolytic function in a
well defined and otherwise healthy hypercholesterolaemic
population. Although the total cholesterol was reduced by 22%
and pravastatin was used at doses that have been shown to
confer major preventative benefits in several large scale clini-
cal trials,34–36 the total serum cholesterol concentration
remained significantly higher than that in the normocholes-
terolaemic population. It may be that a greater reduction in
cholesterol concentrations would have facilitated a significant
improvement in endothelium dependent vasodilatation. How-
ever, the mean cholesterol concentrations of the patients in
WOSCOPS were similar to those in the present study and the
relative risk reduction in ischaemic events is the same across a
broad range of cholesterol concentrations.35 Moreover, it
appears that statins do not just lower cholesterol and may
have many ancillary vascular actions.37 Finally, since we did
not observe a significant difference in t-PA release between
hypercholesterolaemic and normocholesterolaemic subjects, it
is unlikely that additional reductions in lipid concentrations,
brought about by higher doses of pravastatin or more potent
statins, would influence the acute release of t-PA.
The influence of lipid lowering therapy on endothelial dys-
function was initially studied in patients with hypercholes-
terolaemia following treatment for 3–6 months.5 6 However,
more recent studies have shown that endothelial dysfunction
can be reversed by statin treatment for six38 or even four
weeks.7 Indeed, two hour treatment with plasma LDL aphaer-
esis is associated with rapid and immediate reversal of
endothelial dysfunction.39 It is therefore unlikely that the
absence of an effect of pravastatin treatment is caused by the
length of treatment and is consistent with a recent
preliminary report from the WOSCOPS that showed no
Table 3 Plasma plasminogen activator inhibitor type 1 (PAI-1) antigen and activity
in patients at baseline and during placebo and pravastatin treatment and in matched
controls
Substance P dose
(pmol/min) Controls
Patients
Baseline Placebo Pravastatin
PAI-1 antigen (ng/ml)
Infused arm 0 23 (9) 40 (10) 47 (12) 48 (15)
2 24 (8) 43 (10) 47 (11) 44 (13)
4 24 (8) 41 (9) 46 (11) 51 (16)
8 29 (10) 39 (9) 46 (12) 46 (14)
Non-infused arm 0 22 (8) 44 (11) 50 (13) 50 (16)
2 23 (8) 40 (9) 51 (12) 51 (18)
4 26 (9) 39 (9) 51 (14) 46 (14)
8 28 (8) 38 (9) 48 (11) 46 (14)
PAI-1 activity (AU/ml)
Infused arm 0 9 (3) 13 (2) 15 (3) 13 (3)
2 10 (4) 10 (2) 16 (3) 13 (2)
4 9 (4) 9 (3) 13 (3) 14 (2)
8 11 (5) 11 (3) 13 (3) 13 (2)
Non-infused arm 0 12 (3) 14 (3) 14 (3) 15 (3)
2 8 (4) 13 (2) 16 (3) 13 (2)
4 11 (5) 10 (3) 14 (2) 13 (3)
8 9 (4) 12 (3) 13 (3) 12 (3)
Data are mean (SEM).
Table 4 Repeatability of t-PA and blood flow responses to substance P
administration in the infused forearm: baseline versus placebo
Substance P dose
(pmol/min) Baseline mean
Placebo
mean
Mean of
differences
Coefficient of
repeatability
t-PA antigen (ng/ml) 0 4.6 (0.8) 4.7 (0.6) 0.5 0.4
2 5.4 (0.8) 5.4 (0.6) 0.1 1.4
4 5.7 (0.9) 6.0 (0.9) 0.6 1.4
8 7.4 (1.1) 7.5 (1.3) 0.1 1.6
t-PA activity (IU/ml) 0 0.5 (0.1) 0.6 (0.1) 0.0 0.2
2 1.3 (0.5) 1.1 (0.4) 0.3 0.6
4 2.0 (0.6) 1.7 (0.9) 0.4 1.2
8 3.4 (1.1) 3.9 (1.4) 0.3 1.4
Absolute forearm blood
flow (ml/100 ml/min)
0 3.5 (0.3) 3.2 (0.3) 0.3 0.6
2 11.2 (0.7) 10.3 (1.3) 0.9 3.0
4 14.4 (1.8) 12.6 (1.5) 1.7 4.6
8 15.7 (1.1) 14.9 (1.5) 0.8 3.4
Change in forearm blood
flow (%)
2 206 (20) 240 (30) 35 48
4 300 (39) 300 (36) 0 68
8 402 (49) 384 (58) 17 76
Data are mean (SEM).
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changes in basal plasma t-PA concentrations despite 12
months’ treatment with pravastatin.40 Moreover, in contrast to
previous studies, we have used a randomised double blind
crossover study design that provides a greater sensitivity to
detect potential differences in responses. The coefficients of
reproducibility are consistent with our previous studies20 41 and
indicate a power sufficient to detect an approximately 20%
change in blood flow and fibrinolytic responses.
In summary, whereas endothelium dependent vasodilata-
tion is abnormal in both cigarette smoking and hypercholes-
terolaemia, acute t-PA release appears to be impaired only by
cigarette smoking.19 These observations support the concept
that endothelial dysfunction is not a homogeneous condition
and may be manifested in differing ways depending on the
nature of the injury. Moreover, the benefits of lipid lowering
treatment in the primary34 and secondary35 36 prevention of
coronary events are unlikely to be mediated by improvements
in endogenous fibrinolysis.
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